Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Healthy movements..
View:
Post by canadafan on Nov 09, 2022 10:00am

Healthy movements..

After almost a 35% run up in 3 days.
A small sell off? 5%
who cares. 

The long game shows improvement after this Friday abstract, followed by Monday KOL presentation 
even saying that.
the solid gains will not come until a partnership or buyout is announced.
with the volumes, probably end up today

Comment by Hcallahan44 on Nov 09, 2022 10:26am
Thanks Canada...but the volume sucks again......its like lucy pulling the football away from Charlie BRown....i get suckered every year.....here is hoping we end up today...but sure doesnt look like it
Comment by Buckhenry on Nov 09, 2022 10:45am
the stock price is going to fluctuate like Callahans mood on here. im here fir the buyout... could care less about daily stock price.
Comment by canadafan on Nov 09, 2022 10:52am
The day is not over. I know a few who were standing back waiting for a pull- back to buy in. regsrdless, as others said, day- day is meaningless. a partnership or buyout will determine the end game. Not market movements   
Comment by inthno on Nov 09, 2022 10:28am
I noticed you predicted up 20% on one of the other boards. Maybe that will pan out by days end, not really too concerned as predictions are tough in this market and especially with this company. Just curious on your thoughts on one thing, you stated solid gains will not come until a partnership or buyout is announced and usually I would agree with you, but do you not think that after this Fiday ...more  
Comment by westcoast1000 on Nov 09, 2022 11:11am
inthno, From my perspective, the KOL could be significant for retail and institutions but not big pharrma itself. IIRC, this Friday further data will be released in a different conference that may show further development for the results of the treatment groups. If so, that would be more significant (to me at least) than what is said in the KOL.
Comment by inthno on Nov 09, 2022 11:57am
Hello and I agree that this Friday data and the KOL will be most significant for retail and the institutions. As for Roche, they already have the updated information and I believe personally that something is already going on behind the scenes whether it be partnering or buyout possibillities. They now have another 3 months of data to work with since the july 28th data cutoff for the original ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities